

## **AMICUS SIGNS DEAL TO REPRESENT ALEXION ACROSS CEE (INCLUDING BALTICS) AND ANNOUNCES CREATION OF RARE DISEASE BUSINESS UNIT**

### **AMICUS ANNOUNCEMENT NO. 23**

**April 15<sup>th</sup>, 2019**

**Baar, Switzerland** – Amicus SA today announces the signing of a Distribution Agreement with Alexion Pharmaceuticals under which Amicus will assume responsibility of Alexion’s commercial portfolio of innovative medicines for patients with rare diseases -- including Soliris<sup>®</sup> (eculizumab), Kanuma<sup>®</sup> (sebelipase alfa) and Strensiq<sup>®</sup> (asfotase alfa). The agreement includes the import, distribution and management of the in-market regulatory and pharmacovigilance requirements of Alexion’s currently-registered products.

As a result of this new agreement, Amicus also announces the formation of a dedicated rare disease business unit within its organization, which will be dedicated to supporting orphan medicines. Several members of Alexion’s talented CEE team, including in Czech, Hungary, Poland and the West Balkans, will join Amicus and form the core team of the company’s newest division.

“I am extremely pleased to not only announce this exciting new agreement with Alexion Pharmaceuticals, but also the formation of our new rare disease division within Amicus,” commented Amicus CEO Jean-Michel Lespinasse. “It marks an important step for Amicus in extending our expertise and offering to rare diseases, with now a portfolio of three outstanding rare disease medicines. We are delighted and honoured to have the opportunity to work with this important global biopharmaceutical company and to continue to support the unique needs of Alexion’s medicines and the patients they treat.”

### **About Alexion**

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS) and anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), and is also developing it for patients with neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition, the company is developing several mid-to-late-stage therapies, including a second complement inhibitor, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare

Immunoglobulin G (IgG)-mediated diseases. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology and metabolic disorders. Alexion has been named to the Forbes list of the World's Most Innovative Companies seven years in a row and is headquartered in Boston, Massachusetts' Innovation District. The company also has offices around the globe and serves patients in more than 50 countries. Further information about Alexion can be found at: [www.alexion.com](http://www.alexion.com).

#### **About Amicus S.A.**

Amicus now operates fully-owned subsidiaries across Central and Eastern Europe, offering cohesive coverage with the exception of Russia and the CIS countries. Sales in 2018 exceeded 71 million Euros and in 2019 should reach 120 million Euros. Established in 2014, Amicus has gathered outstanding pharmaceutical, rare disease, medical device and OTC / consumer healthcare talent under one roof. The company specializes in representing research-based pharmaceutical, biotech, orphan, medical equipment and self-care brands. For more info about Amicus, please visit: [www.amicuspharma.eu](http://www.amicuspharma.eu)

#### **Contact:**

**Maja Boskovic, Public Affairs Officer, Amicus**

Maja.Boskovic@amicuspharma.eu, Tel: +381 11 4426 321

#### **Note on Unsubscribing from Amicus Announcement Mailing List**

In accordance with GDPR (General Data Protection Regulation) provisos of the EU, we will be sending out in May, 2019 an opt in / opt out (unsubscribe) message to all current recipients of Amicus announcements. Should you wish to unsubscribe / opt out before that, please send to [Maja.Boskovic@amicuspharma.eu](mailto:Maja.Boskovic@amicuspharma.eu) a one-line message „Please unsubscribe me“ and your email address will be promptly removed from our mailing list.